DUBLIN, Nov. 9, 2022 /PRNewswire/ — The “Peripheral Neuropathy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030” report has been added to ResearchAndMarkets.com’s offering.
General population studies have reported that 7 to 8% adults currently have chronic neuropathic pain, where the reported incidence is of 8 cases per 1,000 individuals per year. In the UK alone, 26% individuals with diabetes experience peripheral neuropathic pain. Globally, this figure translates to approximately 50 million individuals, which will further increase as is anticipated that the prevalence of diabetes will grow to an estimated 4.4% by 2030.
Anticonvulsant pregabalin (Lyrica, Pfizer) is among the most widely spread drug for neuropathic pain. Drug manufacturers and developers are thus required to demonstrate improved efficacy to patients while simultaneously reporting cost-benefit to insurers and regulatory bodies. In terms of market competition, the Existing brands are being continually expanded across geographies. Commercialization of pipeline entities into the market will somewhat offset generic erosion.
The report offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2022 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of treatment and different geographies. The drug types studied for analyzing the overall global peripheral neuropathy market are segmented into pharmacological therapies and non-pharmacological therapies. Pharmacological therapies includes pain reliever, anti-seizure medication, antidepressants. Non Pharmacological therapies transcutaneous electrical …